Two chromatographic techniques were developed and validated for simultaneous determination of the newly co-formulated antidiabetic combination linagliptin and empagliflozin in their pure form and film-coated tables. The first technique was UPLC; the separation and resolution of both analytes were achieved using a Zorbax eclipse plus C column applying an isocratic elution based on phosphate buffer pH 4-acetonitrile (65:35, v/v) as a running mobile phase at flow rate 1.5 ml/min and the effluent was monitored at 220 nm. Augmentation of Lean Six Sigma with UPLC and HPTLC methods had a major impact on the development of robust specifications to ensure that the quality at six sigma level has a high level of statistical confidence and target performance. On the chromatogram, empagliflozin and linagliptin appeared at retention times of 1.417 and 2.453 min, respectively. The second technique was HPTLC; both analytes were fairly well resolved and separated using a developing mobile phase composed of ethyl acetate-chloroform-acetonitrile (55:25:20 by volume). The values of retention factor (R ) were 0.29 and 0.53 for linagliptin and empagliflozin, respectively. All variables were investigated to adjust the whole conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bmc.5102DOI Listing

Publication Analysis

Top Keywords

linagliptin empagliflozin
12
uplc hptlc
8
lean sigma
8
mobile phase
8
determination linagliptin
4
empagliflozin
4
empagliflozin uplc
4
hptlc techniques
4
techniques aided
4
aided lean
4

Similar Publications

Micellar liquid chromatography (MLC) has proven beneficial efficiency and ecological impact for routine quality control activities. In the proposed study, cyrene was investigated for the first time, together with other green additives, as a novel safe organic solvent in reversed-phase MLC. Quality-by-design (QbD) approach screened their effect on the separation performance.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the prescription patterns of noninsulin antidiabetic medications among 155,381 Colombian patients with type 2 diabetes mellitus (T2DM), primarily focusing on the most commonly prescribed drugs and their usage in combination therapy.
  • - Metformin emerged as the most frequently prescribed antidiabetic, followed by empagliflozin, sitagliptin, linagliptin, and dapagliflozin, with a significant portion of patients (55.5%) receiving combinations of two or three medications.
  • - Despite advancements in treatment guidelines, many T2DM patients with related cardiovascular conditions are not receiving optimal antidiabetic therapy, indicating a need for better access to drugs that might reduce cardiovascular risk, like sodium
View Article and Find Full Text PDF

Diarrhea is a common illness for travelers. Traveler's diarrhea is typically defined as experiencing at least three unformed stools per day during a stay abroad or within 10 days of returning from the destination. In this review, we consulted five databases, namely, Medicine Complete, Medscape, Drugs.

View Article and Find Full Text PDF

Bayesian borrowing analyses have an important role in the design and analysis of pediatric trials. This paper describes use of a prespecified Pharmacometrics Enhanced Bayesian Borrowing (PEBB) analysis that was conducted to overcome an expectation for reduced statistical power in the pediatric DINAMO trial due to a greater than expected variability in the primary endpoint. The DINAMO trial assessed the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versus placebo on glycemic control (change in HbA1c over 26 weeks) in young people with type 2 diabetes (T2D).

View Article and Find Full Text PDF

Background: Monotherapy to treat obesity-associated liver insult is limited.

Objectives: In diet-induced obese mice showing metabolic dysfunction-associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium-glucose cotransporter-2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase-4 inhibitor (DPP4i, linagliptin, L), and glucagon-like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).

Methods: Male 3-month-old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high-fat (HF, n = 30) diet.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!